UBS Group AG Purchases 421,254 Shares of Embecta Corp. $EMBC

UBS Group AG increased its holdings in shares of Embecta Corp. (NASDAQ:EMBC) by 200.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 630,994 shares of the company’s stock after acquiring an additional 421,254 shares during the period. UBS Group AG’s holdings in Embecta were worth $7,496,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Ameriprise Financial Inc. boosted its stake in Embecta by 439.1% in the 2nd quarter. Ameriprise Financial Inc. now owns 709,849 shares of the company’s stock valued at $6,878,000 after buying an additional 578,174 shares in the last quarter. Jefferies Financial Group Inc. grew its stake in Embecta by 40.4% during the third quarter. Jefferies Financial Group Inc. now owns 1,884,875 shares of the company’s stock worth $26,596,000 after buying an additional 542,162 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Embecta during the fourth quarter worth approximately $5,178,000. Teacher Retirement System of Texas boosted its holdings in shares of Embecta by 365.7% in the 3rd quarter. Teacher Retirement System of Texas now owns 372,451 shares of the company’s stock worth $5,255,000 after acquiring an additional 292,477 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Embecta during the 3rd quarter worth approximately $3,547,000. 93.83% of the stock is owned by institutional investors and hedge funds.

Embecta Stock Down 3.5%

Shares of EMBC stock opened at $3.03 on Tuesday. Embecta Corp. has a 12-month low of $2.99 and a 12-month high of $15.55. The firm has a fifty day moving average of $7.91 and a 200-day moving average of $10.52. The firm has a market capitalization of $179.76 million, a price-to-earnings ratio of 1.59 and a beta of 1.09.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.15). The business had revenue of $221.80 million for the quarter, compared to analyst estimates of $235.67 million. Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The business’s quarterly revenue was down 14.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.70 EPS. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. Research analysts expect that Embecta Corp. will post 1.58 earnings per share for the current year.

Embecta Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 15th. Stockholders of record on Thursday, May 28th will be given a dividend of $0.01 per share. The ex-dividend date of this dividend is Thursday, May 28th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 1.3%. Embecta’s dividend payout ratio (DPR) is currently 2.11%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Bank of America lowered their target price on Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a research note on Monday. Weiss Ratings cut Embecta from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, May 6th. Mizuho dropped their target price on Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Zacks Research cut Embecta from a “hold” rating to a “strong sell” rating in a report on Friday, May 8th. Finally, Wall Street Zen lowered shares of Embecta from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Strong Sell” and a consensus target price of $11.00.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.